Cancer Advisor

Last revised: August 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published...

OneDayMD Cancer Edition · Evidence briefing · 21 September 2026 Quick answer. We are not on the verge of a single shot that “cures cancer,” because cancer is not one disease. We are on a real path to end cancer as a leading cause of death — if prevention, earlier interception, precision drugs, immune memory, and access move together. U.S. cancer death rates have already fallen 35% since 1991. The 2026 toolkit is no longer chemotherapy plus hope. The remaining work is biological, operational, and political — not motivational.

A critical spotlight on the standout cases from our 760-case compilation — including the most heavily pretreated, "no options left" patients — with an honest look at what the evidence can and cannot tell us. Quick Answer Of the 760 case reports describing antiparasitic drug protocols (fenbendazole, ivermectin, or mebendazole) in patients with cancer, the most clinically notable outcomes fall into three broad categories: (1) rapid complete or near-complete remissions in patients whose disease had progressed despite conventional therapy, (2) imaging-confirmed tumor regressions ranging from 40% to 99%, and (3) patients receiving hospice care or given a prognosis of only weeks to live who survived substantially longer than expected. Only a small fraction of these 760 cases have been published in peer-reviewed journals; the remainder are self-reported anecdotal accounts. Accordingly, these reports should be regarded as hypothesis-generating observations rather than evid...

Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...